UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is a single-arm, multicenter, open-labeled clinical study of UTD1 combined with Capecitabine in metastatic HER2-negative breast cancaner patients with brain metastases. This study aims to evaluate the efficacy and safety of UDT1 combined with capecitabine in metastatic HER2-negative breast cancer patients with brain metastases.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-70 lat
- •Potwierdzony histologicznie rak piersi z ujemnym HER2, nawrotowy lub z przerzutami
- •Co najmniej jedna mierzalna zmiana w ośrodkowym układzie nerwowym
- •Dobry stan sprawności (ECOG 0-2)
- •Przerzuty do mózgu spełniające określone kryteria (nieleczone bez potrzeby pilnego leczenia, lub leczone bez progresji)
- •Prawidłowe wyniki badań krwi, wątroby i nerek
- •Zgoda na skuteczną antykoncepcję
- •Oczekiwane przeżycie >12 tygodni
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- April 25, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Quchang Ouyang
Changsha, China
Trial contact
Quchang Ouyang
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.